Quick Answer
Coya Therapeutics, Inc. reported Stockholders Equity of $43.03 million for fiscal year 2025.
Coya Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $43.03M | +8.7% |
| 2024 | $39.58M | +11.1% |
| 2023 | $35.64M | +524.6% |
| 2022 | -$8.39M | -330.4% |
| 2021 | $3.64M | -56.1% |
| 2020 | $8.30M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.28M | -14.8% | -3.6% |
| June 30, 2025 | $28.31M | -19.7% | -15.2% |
| March 31, 2025 | $33.37M | +3.0% | -15.7% |
| December 31, 2024 | $39.58M | +11.1% | +23.6% |
| September 30, 2024 | $32.01M | +217.3% | -9.2% |
| June 30, 2024 | $35.26M | +166.1% | +8.8% |
| March 31, 2024 | $32.39M | +100.5% | -9.1% |
| December 31, 2023 | $35.64M | +524.6% | +253.2% |
- Coya Therapeutics, Inc. showed an increase of +8.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Coya Therapeutics, Inc.’s stockholders equity has grown by 418.3% (from $8.30 million to $43.03 million).
- The most recent figure is from Coya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: